Earnings summaries and quarterly performance for Envoy Medical.
Executive leadership at Envoy Medical.
Board of directors at Envoy Medical.
Research analysts covering Envoy Medical.
Recent press releases and 8-K filings for COCH.
Envoy Medical Updates on Fully-Implanted Cochlear Implant Development
COCH
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Envoy Medical, Inc. is developing the Acclaim® CI, a first-of-its-kind fully-implanted cochlear implant designed to transform the multi-billion-dollar cochlear implant market.
- The pivotal clinical trial for the Acclaim® CI is underway, with full enrollment of 56 patients anticipated in Q1 2026 and FDA approval expected by the end of 2027.
- The U.S. Total Addressable Market (TAM) for the Acclaim® CI is estimated at $84 billion, targeting 2.8 million people with severe or profound hearing loss, representing a largely untapped market.
- The company projects achieving profitability at 2,500 Acclaim® CI units sold annually, which would generate $75 million in revenue based on an anticipated average selling price of ~$30,000.
Dec 16, 2025, 2:47 PM
Envoy Medical Receives Nasdaq Listing Extension
COCH
Delisting/Listing Issues
New Projects/Investments
- Envoy Medical, Inc. (NASDAQ: COCH) has received a positive listing determination from the Nasdaq Hearings Panel, granting the company's request for continued listing on the Nasdaq Stock Market.
- The company has been granted an extension until February 23, 2026, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2), which pertains to the $35 million market value of listed securities requirement.
- The Panel's decision considered several key developments, including Envoy Medical's recent equity capital raises, debt extinguishment, and the FDA's approval for the final stage of the Acclaim® cochlear implant clinical trial.
Oct 28, 2025, 1:22 PM
Envoy Medical Announces Up to $16 Million Registered Direct Offering
COCH
- Envoy Medical, Inc. (NASDAQ: COCH) announced a registered direct offering of 3,007,524 shares of Class A common stock at a purchase price of $1.33 per share, along with a concurrent private placement of unregistered warrants to purchase up to 9,022,572 shares of Class A common stock, also at an exercise price of $1.33 per share.
- The offering is expected to generate $4.0 million in gross proceeds, with a potential for an additional $12 million if the unregistered warrants are fully exercised.
- The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
- The offering is anticipated to close on or about October 9, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Oct 9, 2025, 1:15 PM
Envoy Medical Receives FDA Approval for Acclaim Cochlear Implant Trial Expansion
COCH
New Projects/Investments
Guidance Update
- Envoy Medical, Inc. received FDA approval to advance its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage, based on promising three-month data from the first 10 patients.
- This approval is expected to shorten the estimated timeline by three to six months and reduce the anticipated capital need by $10-$15 million.
- The company expects to complete full enrollment by early 2026 for the final stage of the trial, which will include an additional 46 participants.
Oct 7, 2025, 2:04 PM
Envoy Medical Announces Registered Direct Offering and Concurrent Private Placement
COCH
- Envoy Medical Inc. (NASDAQ: COCH) announced a registered direct offering of 1,908,402 shares of Class A common stock at a purchase price of $1.31 per share, expected to generate approximately $2.5 million in gross proceeds.
- In a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,725,206 shares of Class A common stock with an exercise price of $1.31 per share.
- If these unregistered warrants are fully exercised, they could provide an additional $7.5 million in gross proceeds.
- The offering is priced at-the-market under Nasdaq rules and is anticipated to close on or about September 23, 2025.
- The net proceeds from the offering are intended for working capital and other general corporate purposes.
Sep 23, 2025, 1:56 PM
Envoy Medical Extinguishes Debt and Announces Board Retirement
COCH
Debt Issuance
Board Change
- On August 25, 2025, Envoy Medical, Inc. extinguished over $32 million in debt (including principal and accrued interest) owed to GAT Funding, LLC, in exchange for a cash payment of $100,000.
- The extinguished debt comprised promissory notes from February 2024, August 2024, and March 2025, with a total outstanding principal balance of $30,800,000 and accrued interest of $1,211,552 as of the effective date.
- This action is expected to strengthen the company's balance sheet and simplify its capital structure by eliminating all term loan obligations without equity conversion.
- Concurrently, Glen A. Taylor, owner of GAT Funding, LLC and the company's largest stockholder, retired from Envoy Medical's Board of Directors effective August 25, 2025.
Aug 26, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more